GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
GS-US-611-6464
Phase 3 small_molecule active
Quick answer
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg for COVID-19 is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- COVID-19
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active